WallStSmart

Abbott Laboratories (ABT)vsInfuSystems Holdings Inc (INFU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 31594% more annual revenue ($45.13B vs $142.40M). ABT leads profitability with a 13.9% profit margin vs 5.5%. ABT appears more attractively valued with a PEG of 1.30. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

INFU

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 7.5
Piotroski: 6/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
INFUUndervalued (+26.5%)

Margin of Safety

+26.5%

Fair Value

$10.36

Current Price

$9.03

$1.33 discount

UndervaluedFair: $10.36Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

INFU1 strengths · Avg: 10.0/10
EPS GrowthGrowth
123.9%10/10

Earnings expanding 123.9% YoY

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

INFU4 concerns · Avg: 3.5/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Market CapQuality
$186.48M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : INFU

The strongest argument for INFU centers on EPS Growth.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : INFU

The primary concerns for INFU are PEG Ratio, Altman Z-Score, Market Cap.

Key Dynamics to Monitor

INFU carries more volatility with a beta of 1.42 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 51/100). INFU offers better value entry with a 26.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

InfuSystems Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

InfuSystem Holdings, Inc., provides infusion pumps and related products and services in the United States and Canada. The company is headquartered in Rochester Hills, Michigan.

Want to dig deeper into these stocks?